Place in therapy of olmesartan
Place in therapy of olmesartanOlmesartan has been de-reimbursed in France since January 2017 following a negative evaluation of its benefit/risk profile compared with other sartans. However, olmesartan is one of the antihypertensive blockbusters in Italy in terms of usage and expenditure. This artic...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
AboutScience Srl
2017-06-01
|
| Series: | Global & Regional Health Technology Assessment |
| Online Access: | http://www.grhta.com/Attach/F27B3FD7-CBC1-424E-BD72-8982CF1077CF/C3BDF191-B2CF-4FB1-8BAA-199417C4722C |